Mabwell, Aditum Launch Kalexo Bio To Advance Dual-Target siRNA Therapy For Cardiovascular Disease
Sept 17 (Reuters) - Mabwell Shanghai Bioscience Co Ltd 688062.SS:
MABWELL BIOSCIENCE AND ADITUM BIO ANNOUNCE FORMATION OF KALEXO BIO TO ADVANCE INNOVATIVE SIRNA THERAPY FOR CARDIOVASCULAR DISORDERS
MABWELL SHANGHAI BIOSCIENCE CO LTD - ELIGIBLE FOR UP TO $1 BILLION IN PAYMENTS
MABWELL SHANGHAI BIOSCIENCE CO LTD - GRANTS KALEXO BIO WORLDWIDE RIGHTS TO 2MW7141
MABWELL SHANGHAI BIOSCIENCE CO LTD - TO RECEIVE $12 MILLION UPFRONT PAYMENTS AND EQUITY STAKE IN KALEXO BIO
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Nvidia Stock: Breaking Down Its Key Risk and Why It’s Still a Compelling Buy in 2026

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Is Novo Nordisk Positioned for Recovery in 2026 Amid Rising Competition and AI Innovations?

Tradingkey






